Targeted Drugs Build on Efficacy Record in Melanoma

September 29, 2014 10:26 PM

15 0

MADRID -- Targeted therapy solidified and clarified its role in the treatment of advanced melanoma, as studies showed superiority over chemotherapy, and that two targeted drugs outperform one.

The immune checkpoint inhibitor nivolumab (Opdivo) had triple the response rate of standard chemotherapy in patients with progressive, unresectable melanoma. Three studies showed that combining a BRAF inhibitor and a MEK inhibitor improves progression-free survival (PFS) as compared with a BRAF inhi...

Read more

To category page